HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Hillhouse Capital Related

439.255

-16.934-3.71%

Number of Gainers:- -

Number of Losers:51

Number of Flat:4

PE:- -

High:456.159

Open:456.159

Low:439.085

Close:456.189

Volume:285.21M

Turnover:5.18B

Market Cap:2.67T

Float Cap:1.97T

Loading ...

Huatai Securities Asset Management Undergoes Another Executive Reshuffle: Si Xiaobin Promoted to Deputy General Manager

CF PharmTech to Partner With JD Health on Product Launches

MT Newswires Live

BRIEF-Everest Medicines Says Unit To Buy Assets For Up To $50 Million

CF PHARMTECH (02652) Enters Strategic Partnership with JD HEALTH

Is Haidilao International Holding (SEHK:6862) Attractive After Mixed Price Moves And DCF Upside?

Simply Wall St.

XINYI ENERGY Sees 4.516 Million Share Purchase by Shanghai Ningquan Asset Management at HK$1.27 Per Share

RS MACALLINE Sees Stake Increase by Renqiao (Beijing) Asset Management

Everest Med Enters Asset Purchase Agreement with Jixing Pharmaceutical Hong Kong

CF PharmTech signs strategic cooperation agreement with JD Health International Inc

Innovent doses first patient in 600-participant Phase 3 IBI128 gout trial versus febuxostat

Innovent Announces First Participant Dosed of Ibi128 (Tigulixostat, Xoi) in Phase 3 Clinical Study

THOMSON REUTERS

Everest Medicines unit to acquire etripamil nasal spray assets for up to USD 50 million

Everest Medicines - Assets Refers to Pharmaceutical Products That Uses Device to Deliver Etripamil by Nasal Spray

THOMSON REUTERS

Everest Medicines - Unit to Buy Assets for up to $50 Mln

THOMSON REUTERS

HANSOH PHARMA's Novel Drug HS-10587 Tablets Receive Clinical Trial Approval from NMPA

Antengene (SEHK:6996) Losses Halve In 1H 2025 Challenging Concerns Over Rich P/S Multiple

Simply Wall St.

Hansoh Pharmaceutical Wins NMPA Approval to Start HS-20152 Injection Clinical Trial for PNH

Hansoh Pharmaceutical - Clinical Trial Approval for Hs-10587 Tablets Issued by Nmpa China

THOMSON REUTERS

China NMPA grants clinical trial approval for Hansoh HS-10587 tablets

DIAGENS-B: Medical Imaging AI Specialist with 8.4 Billion Float Shares - New Stock Analysis for March 2026 (02526.HK)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1583/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"Hillhouse Capital Related","latestPrice":439.2546,"timestamp":1774238399661,"preClose":456.18893,"halted":0,"volume":285209842,"delay":0,"changeRate":-0.037121,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Noon Closed","change":-16.934326,"latestTime":"03-23 12:00:00","open":456.15918,"high":456.15918,"low":439.08548,"amount":5184835647,"amplitude":0.037427,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774242000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774229400000,1774238400000],[1774242000000,1774252800000]],"pbRate":2.147644,"peRate":32.470281,"turnoverRate":0.002056,"increases":0,"decrements":51,"flats":1,"marketCap":2672186746784,"floatMarketCap":1970479153888},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":456.15918,"amplitude":0.037427,"preClose":456.18893,"low":439.08548,"pbRate":"2.147644","latestPrice":439.2546,"volume":285209842,"delay":0,"open":456.15918,"prevYearClose":503.90085,"prevWeekClose":456.189,"prevMonthClose":490.497,"prevQuarterClose":503.901,"fiveDayClose":464.06,"twentyDayClose":515.572,"sixtyDayClose":519.409,"secType":"PLATE","market":"HK","turnoverRate":0.002056,"peRate":32.470281,"marketCap":2672186746784,"floatMarketCap":1970479153888,"timestamp":1774238399661,"nameCN":"Hillhouse Capital Related"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":0,"down":51,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1199845875","title":"Huatai Securities Asset Management Undergoes Another Executive Reshuffle: Si Xiaobin Promoted to Deputy General Manager","url":"https://stock-news.laohu8.com/highlight/detail?id=1199845875","media":"Deep News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199845875?lang=en_us&edition=fundamental","pubTime":"2026-03-23 09:52","pubTimestamp":1774230751,"startTime":"0","endTime":"0","summary":"Huatai Securities (Shanghai) Asset Management Co., Ltd. recently announced a change in its senior management team, appointing Si Xiaobin as Deputy General Manager effective March 20, 2026. This...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601688","BK1258","LU0871576103.HKD","LU1328615791.USD","LU1580142542.USD","BK0012","LU2148510915.USD","BK0276","LU1781817850.SGD","LU1979443071.USD","LU0531971595.HKD","LU1934453819.USD","LU0164865239.USD","BK0028","BK1583","LU1064130708.USD","LU1064131003.USD","LU1808992512.USD","09983","BK1542","BK0188","LU0039217434.USD","BK0183","BK1229"],"gpt_icon":0},{"id":"2621287887","title":"CF PharmTech to Partner With JD Health on Product Launches","url":"https://stock-news.laohu8.com/highlight/detail?id=2621287887","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621287887?lang=en_us&edition=fundamental","pubTime":"2026-03-23 09:45","pubTimestamp":1774230357,"startTime":"0","endTime":"0","summary":"CF PharmTech  is partnering with JD Health International  to launch a number of respiratory and rhinology therapeutic products, according to a Hong Kong bourse filing Monday.The firm said JD Health will serve as the exclusive online launch platform for a number of products over the next three years.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4122","HK0000306701.USD","BK1589","06618","BK4503","BK4526","SGXZ86797644.SGD","BK4509","BK4524","LU0106959298.USD","IE0008368742.USD","BK1247","BK1591","BK4579","02652","BK4585","LU0326950275.SGD","BK4588","BK1583","LU0588546209.SGD","BK4505","SG9999002463.SGD","BK4551","BK1615","KJD","BK1142","LU0456827905.SGD","BK4614","LU0051755006.USD","86618","BK1191","BK4220","BK1515","BK1571","BK4531","IE00BGV7N243.SGD","LU1688375341.USD","BK4504","LU0244354667.USD","LU1188198961.HKD","BK4093","BK4558","LU1880383366.USD","HK0000320223.HKD","LU0307460666.USD","HK0000320264.USD","LU0463099449.HKD","SGXZ62798434.SGD","HK0000306685.HKD"],"gpt_icon":0},{"id":"2621425747","title":"BRIEF-Everest Medicines Says Unit To Buy Assets For Up To $50 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621425747","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621425747?lang=en_us&edition=fundamental","pubTime":"2026-03-23 08:29","pubTimestamp":1774225753,"startTime":"0","endTime":"0","summary":"BRIEF-Everest Medicines Says Unit To Buy Assets For Up To $50 MillionMarch 23  - Everest Medicines Ltd 1952.HK:UNIT TO BUY ASSETS FOR UP TO $50 MILLIONASSETS REFERS TO PHARMACEUTICAL PRODUCTS THAT USES DEVICE TO DELIVER ETRIPAMIL BY NASAL SPRAYFurther company coverage: 1952.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40900N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01952","BK1574","BK1583"],"gpt_icon":0},{"id":"1167098882","title":"CF PHARMTECH (02652) Enters Strategic Partnership with JD HEALTH","url":"https://stock-news.laohu8.com/highlight/detail?id=1167098882","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167098882?lang=en_us&edition=fundamental","pubTime":"2026-03-23 08:18","pubTimestamp":1774225105,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) has announced the formal signing of a strategic cooperation agreement with JD Health International Inc. (JD HEALTH) on March 20, 2026. Under this agreement, JD HEALTH will serve...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","LU0051755006.USD","06618","BK1615","BK1571","86618","BK1591","LU0456827905.SGD","BK1589","SGXZ86797644.SGD","BK1247","BK1515","02652","BK1583","SGXZ62798434.SGD","BK1142"],"gpt_icon":0},{"id":"2621408607","title":"Is Haidilao International Holding (SEHK:6862) Attractive After Mixed Price Moves And DCF Upside?","url":"https://stock-news.laohu8.com/highlight/detail?id=2621408607","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621408607?lang=en_us&edition=fundamental","pubTime":"2026-03-23 08:18","pubTimestamp":1774225098,"startTime":"0","endTime":"0","summary":"Wondering if Haidilao International Holding at HK$15.85 is a bargain or a value trap? This article breaks down what the current price might actually reflect.\nThe stock has had a mixed run, with a 10% year-to-date gain alongside 1% and 6% declines over the past 7 days and 30 days, and a 2.6% decline over the last year plus a 64.6% decline over five years that many investors still have in mind.\nRecent coverage has focused on Haidilao International Holding as a Hong Kong listed consumer...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/4214000-choice1-main-header/1585186691957","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4214000-choice1-main-header/1585186691957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/consumer-services/hkg-6862/haidilao-international-holding-shares/news/is-haidilao-international-holding-sehk6862-attractive-after","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/consumer-services/hkg-6862/haidilao-international-holding-shares/news/is-haidilao-international-holding-sehk6862-attractive-after","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1233","BK1591","LU2488822045.USD","06862","BK1583","BK1589","DCF","BK1604"],"gpt_icon":0},{"id":"1185085560","title":"XINYI ENERGY Sees 4.516 Million Share Purchase by Shanghai Ningquan Asset Management at HK$1.27 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1185085560","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185085560?lang=en_us&edition=fundamental","pubTime":"2026-03-23 08:13","pubTimestamp":1774224799,"startTime":"0","endTime":"0","summary":"Latest data from the Hong Kong Stock Exchange shows that on March 16, Shanghai Ningquan Asset Management increased its stake in XINYI ENERGY (03868) by 4.516 million shares, at a price of HK$1.27 per...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1229","03868","BK1554","BK1154","BK1594","BK1542","09983","BK1583","BK1258"],"gpt_icon":0},{"id":"1134479112","title":"RS MACALLINE Sees Stake Increase by Renqiao (Beijing) Asset Management","url":"https://stock-news.laohu8.com/highlight/detail?id=1134479112","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134479112?lang=en_us&edition=fundamental","pubTime":"2026-03-23 08:11","pubTimestamp":1774224717,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on March 18, Renqiao (Beijing) Asset Management Co., Ltd. increased its holdings in RS MACALLINE (01528) by 1,334,800 shares. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01528","BK1229","BK1583","BK1542","BK1501","BK1258","09983"],"gpt_icon":0},{"id":"1145799286","title":"Everest Med Enters Asset Purchase Agreement with Jixing Pharmaceutical Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=1145799286","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145799286?lang=en_us&edition=fundamental","pubTime":"2026-03-23 08:08","pubTimestamp":1774224509,"startTime":"0","endTime":"0","summary":"Everest MED (01952) has announced that on March 23, 2026, the buyer, a wholly-owned subsidiary of the company, entered into an asset purchase agreement with the seller, Jixing Pharmaceutical Hong...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","01952","BK1161"],"gpt_icon":0},{"id":"2621747893","title":"CF PharmTech signs strategic cooperation agreement with JD Health International Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2621747893","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621747893?lang=en_us&edition=fundamental","pubTime":"2026-03-23 08:04","pubTimestamp":1774224298,"startTime":"0","endTime":"0","summary":"CF PharmTech signed a strategic cooperation agreement with JD Health on March 20, 2026.JD Health will act as the exclusive online launch platform for several new respiratory and rhinology products over the next three years.Support under the agreement includes online launch sales and patient services, plus prescription management and patient administration.The parties will also explore internet-based chronic disease management models.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL64hRqB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0048580855.USD","LU0164880469.USD","BK1615","IE00B29SXG58.USD","SGXZ62798434.SGD","LU0431992006.USD","86618","06618","89618","BK1247","BK1610","LU0588545490.SGD","LU0293314216.USD","LU0084288322.USD","LU0791590937.USD","02652","LU2242644610.SGD","LU0320764755.SGD","LU0499858438.USD","LU1328277881.USD","LU0456846285.SGD","LU0588545904.SGD","LU0871576103.HKD","LU0469268626.HKD","BK1619","LU1282651048.USD","LU0531971595.HKD","SG9999002562.SGD","LU1023057109.AUD","LU0456827905.SGD","LU0307460666.USD","LU0417516902.SGD","LU0149721374.USD","LU1366334578.USD","JD","LU0315178854.USD","LU0128522157.USD","LU0672654166.SGD","LU0572944931.SGD","LU0828237510.HKD","BK1575","BK1191","LU1044875133.USD","LU0314109678.HKD","LU0708995583.HKD","LU1720050803.USD","LU1366334651.USD","LU0650527681.SGD","BK1583","IE00BGV7N243.SGD","BK1249","LU1282651121.HKD","LU0228367735.SGD","LU0315179316.USD","LU1303224171.USD","LU0051755006.USD","LU0039217434.USD","LU1481107354.HKD","LU1794554557.SGD","LU0320764599.SGD","LU0359201612.USD","BK1591","LU0228659784.USD","SG9999001226.SGD","LU0345775950.USD","LU1642822792.SGD","LU0499858602.USD","BK1142","LU0865486749.SGD","LU0348825331.USD","BK1588","LU1251922891.USD","LU0791591158.USD","LU1044876610.USD","LU0417516738.SGD","LU0211977185.USD","LU0359201885.HKD","LU0594300419.USD","LU1224444064.USD","LU0348735423.USD","BK1502","LU1808992512.USD","LU0163747925.USD","SG9999002828.SGD","IE00B3M56506.USD","LU0588546209.SGD","IE0032431581.USD","BK1589","LU0384037296.USD","LU0231483743.USD","SGXZ86797644.SGD","LU1044874839.SGD","LU1770036033.HKD","LU2039709279.SGD","LU0140636845.USD","LU0370786039.SGD","LU0488056044.USD","LU1813983027.USD","LU1282649810.SGD","LU0588545730.USD","LU2257852520.SGD","LU1282649067.USD","LU0543330483.HKD","LU0359202008.SGD","LU0029875118.USD","LU0345776255.USD","LU1719994722.HKD","LU0348805143.USD","LU1770034418.SGD","LU0259732245.USD","LU0052750758.USD","LU0164865239.USD","LU0456842615.SGD","BK1515","LU0327786744.USD","LU0868486357.SGD","BK1571"],"gpt_icon":1},{"id":"2621742072","title":"Innovent doses first patient in 600-participant Phase 3 IBI128 gout trial versus febuxostat","url":"https://stock-news.laohu8.com/highlight/detail?id=2621742072","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621742072?lang=en_us&edition=fundamental","pubTime":"2026-03-23 08:00","pubTimestamp":1774224021,"startTime":"0","endTime":"0","summary":"Innovent reported that the first participant has been dosed in a randomized, double-blind, multi-center Phase 3 study of tigulixostat , a xanthine oxidase inhibitor, in Chinese patients with gout.The trial plans to enroll 600 patients and will randomize them 1:1 to tigulixostat 100 mg or febuxostat 40 mg for 24 weeks.The primary endpoint is the proportion of patients achieving serum uric acid below 360 μmol/L at week 24.Phase 2 data were previously presented at the 2025 Asia-Pacific League of Associations for Rheumatology conference, and the Phase 3 study is intended to assess longer-term outcomes over a one-year treatment period.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL10gZhx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828714.EUR","LU2097828474.EUR","BK1583","LU2097828557.USD","LU0502904849.HKD","LU2097828805.USD","LU2328871848.SGD","LU0455707207.USD","LU2488822045.USD","HK0000165453.HKD","01911","BK1589","BK1147","LU1969619763.USD","LU2242644610.SGD","01801","LU2097828631.EUR","BK1161"],"gpt_icon":0},{"id":"2621024742","title":"Innovent Announces First Participant Dosed of Ibi128 (Tigulixostat, Xoi) in Phase 3 Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2621024742","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621024742?lang=en_us&edition=fundamental","pubTime":"2026-03-23 08:00","pubTimestamp":1774224000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nTUA6PRVH5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2097828474.EUR","LU2097828805.USD","LU2242644610.SGD","HK0000165453.HKD","LU2097828631.EUR","LU0455707207.USD","LU2097828714.EUR","LU2488822045.USD","BK1589","LU2328871848.SGD","01801","LU0502904849.HKD","LU2097828557.USD","LU1969619763.USD","BK1583","BK1161"],"gpt_icon":0},{"id":"2621723742","title":"Everest Medicines unit to acquire etripamil nasal spray assets for up to USD 50 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621723742","media":"Reuters","labels":["corporation","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621723742?lang=en_us&edition=fundamental","pubTime":"2026-03-23 07:58","pubTimestamp":1774223924,"startTime":"0","endTime":"0","summary":"Everest Medicines’ wholly owned Singapore subsidiary signed an asset purchase agreement to acquire intellectual property and product inventory related to an etripamil nasal spray product in China.Transaction consideration is up to USD 50.0 million, comprising USD 30.0 million upfront and up to USD 20.0 million in development milestones.Milestones include USD 15.0 million tied to NMPA NDA approval for paroxysmal supraventricular tachycardia and USD 3.0 million tied to NMPA acceptance of a marketing authorization application for a localized version.As part of the closing, the buyer will assume certain obligations under assigned contracts, including up to USD 92.0 million in sales milestones.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nNDL2f33kd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","01952","BK1161"],"gpt_icon":0},{"id":"2621742720","title":"Everest Medicines  - Assets Refers to Pharmaceutical Products That Uses Device to Deliver Etripamil by Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2621742720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621742720?lang=en_us&edition=fundamental","pubTime":"2026-03-23 07:58","pubTimestamp":1774223923,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nFWN40900N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01952","BK1583","BK1574","BK1161"],"gpt_icon":0},{"id":"2621074274","title":"Everest Medicines - Unit to Buy Assets for up to $50 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2621074274","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621074274?lang=en_us&edition=fundamental","pubTime":"2026-03-23 07:58","pubTimestamp":1774223923,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nFWN40900N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","01952","BK1583"],"gpt_icon":0},{"id":"1128772586","title":"HANSOH PHARMA's Novel Drug HS-10587 Tablets Receive Clinical Trial Approval from NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1128772586","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128772586?lang=en_us&edition=fundamental","pubTime":"2026-03-23 07:34","pubTimestamp":1774222452,"startTime":"0","endTime":"0","summary":"HANSOH PHARMA (03692) announced that its self-developed Class 1 innovative drug, HS-10587 tablets, has obtained a clinical trial approval notice issued by the National Medical Products Administration...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03692","BK1589","BK1583"],"gpt_icon":0},{"id":"2621740867","title":"Antengene (SEHK:6996) Losses Halve In 1H 2025 Challenging Concerns Over Rich P/S Multiple","url":"https://stock-news.laohu8.com/highlight/detail?id=2621740867","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621740867?lang=en_us&edition=fundamental","pubTime":"2026-03-23 07:14","pubTimestamp":1774221288,"startTime":"0","endTime":"0","summary":"Antengene (SEHK:6996) has opened FY 2025 with first half revenue of C¥53.2 million and a basic EPS loss of C¥0.12 per share, setting the tone for how investors will assess its path toward profitability. Over the past few reporting periods, the company has seen revenue move from C¥60.8 million in 1H 2024 to C¥31.2 million in 2H 2024 and C¥53.2 million in 1H 2025, while basic EPS has shifted from a loss of C¥0.27 to a loss of C¥0.24 and then to a loss of C¥0.12. With revenue still modest and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6996/antengene-shares/news/antengene-sehk6996-losses-halve-in-1h-2025-challenging-conce","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6996/antengene-shares/news/antengene-sehk6996-losses-halve-in-1h-2025-challenging-conce","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1583","06996","BK1191","BK1574"],"gpt_icon":0},{"id":"2621447247","title":"Hansoh Pharmaceutical Wins NMPA Approval to Start HS-20152 Injection Clinical Trial for PNH","url":"https://stock-news.laohu8.com/highlight/detail?id=2621447247","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621447247?lang=en_us&edition=fundamental","pubTime":"2026-03-23 07:03","pubTimestamp":1774220600,"startTime":"0","endTime":"0","summary":"Hansoh said China’s drug regulator granted clinical trial clearance for its HS-20152 injection in paroxysmal nocturnal hemoglobinuria.The approval enables the company to advance an internally developed new drug candidate into clinical-stage development.Progress in this rare-disease indication could broaden Hansoh’s pipeline positioning in specialized therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nNDL36mF9M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03692","BK1583","BK1589"],"gpt_icon":0},{"id":"2621474479","title":"Hansoh Pharmaceutical - Clinical Trial Approval for Hs-10587 Tablets Issued by Nmpa China","url":"https://stock-news.laohu8.com/highlight/detail?id=2621474479","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621474479?lang=en_us&edition=fundamental","pubTime":"2026-03-23 07:01","pubTimestamp":1774220478,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nFWN40A02X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1589","BK1583","BK1191","03692"],"gpt_icon":0},{"id":"2621744797","title":"China NMPA grants clinical trial approval for Hansoh HS-10587 tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2621744797","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621744797?lang=en_us&edition=fundamental","pubTime":"2026-03-23 07:01","pubTimestamp":1774220468,"startTime":"0","endTime":"0","summary":"Hansoh said China’s National Medical Products Administration granted clinical trial approval for HS-10587 tablets.The drug candidate is intended for clinical trials in MTAP-deleted advanced solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nNDL8PLW9Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03692","BK1589","BK1583"],"gpt_icon":0},{"id":"1198056909","title":"DIAGENS-B: Medical Imaging AI Specialist with 8.4 Billion Float Shares - New Stock Analysis for March 2026 (02526.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=1198056909","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198056909?lang=en_us&edition=fundamental","pubTime":"2026-03-22 22:31","pubTimestamp":1774189911,"startTime":"0","endTime":"0","summary":"This analysis is conducted from an institutional perspective, focusing on the company's business operations and market positioning. Readers are encouraged to follow for more institutional-grade...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02526","159883","BK1583","BK1574","BK1189","09996","BK1222","02251","BK1100","09997"],"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":1,"totalSize":326,"code":"91000000","status":"200"}]}}